7,647.25

+33.25

+0.44%

52,071.00

+153.00

+0.29%

28,775.75

+241.75

+0.85%

Russell 2000 Futures

2,835.00

+13.70

+0.49%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,921.10

+22.20

+0.57%

78,066.64

+208.05

+0.27%

Crude Oil Dec 26

100.73

-3.39

-3.26%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)

50.750 +0.050 (+0.10%)

As of 2:14:08 PM GMT+8. Market Open.

Loading Chart for 1276.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal

Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

Top China Biopharma Stocks to Watch, According to Bernstein

Top China Biopharma Stocks to Watch, According to Bernstein

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Mobilize your Website

View Site in Mobile | Classic

Share by: